BFC Planning’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
Other funds holding ABCL
BFC Planning's ABCL Position: Q3 2026 in Review
BFC Planning reduced its AbCellera Biologics (ABCL) stake by 34% in Q3 2026, selling an estimated $47.4K and leaving 9,500 shares worth $139K. The position accounts for 0.01% of the portfolio, ranked #1091.
BFC Planning first reported a position in ABCL in Q2 2026 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.
- BFC Planning held 9,500 shares of AbCellera Biologics worth $139K as of Q3 2026.
- BFC Planning sold 5,000 AbCellera Biologics shares in Q3 2026, an estimated $47.4K.
- AbCellera Biologics made up 0.01% of BFC Planning's portfolio in Q3 2026, its #1091 holding.
- BFC Planning first reported a position in AbCellera Biologics in Q2 2026 and has held it in 2 quarters since.
- 115 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.